Tags · Access
formulary
The list that decides what is covered and at what tier.
Related in this group: insurance · prior authorisation · appeals · cost per milligram · compounding · shortage · NHS · EMA · FDA · MHRA · personal import · telehealth
56 topics · page 2 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
|
+90 | 99 | 32k | 9mo |
|
Revisiting: Reading a denial letter as a specification for your appeal
Posting this under the heading it deserves: Revisiting: Reading a denial letter as a specification for your appeal Everything below is what sits behind that. A coverage question with the paperwork detail…
|
+125 | 138 | 9.4k | 10mo |
|
Appeal templates and why they are deliberately unemotional — one year on
Appeal templates and why they are deliberately unemotional — one year on Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…
|
2 | 4.1k | 11mo | |
|
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
|
+22 | 29 | 356 | 11mo |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+85 | 92 | 5.5k | 11mo |
|
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
|
+24 | 28 | 50k | 12mo |
|
[2026 update] Documentation that materially improves an appeal's chances
On the subject in the title: Documentation that materially improves an appeal's chances Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 2.4k | 13mo | |
|
Pen wastage and its effect on real cost — the long version
Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…
|
2 | 34k | 13mo | |
|
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this…
|
+21 | 25 | 55k | 13mo |
|
Cost per milligram, computed honestly across formats — a second dataset
Cost per milligram, computed honestly across formats — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
2 | 27k | 13mo | |
|
[2026 update] An appeal that failed, and what I would do differently
Posting this under the heading it deserves: An appeal that failed, and what I would do differently Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+152 | 159 | 2.5k | 13mo |
|
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
+4 | 8 | 658 | 14mo |
|
Cost per milligram, computed honestly across formats — the long version
Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
+111 | 124 | 24k | 14mo |
|
Coverage for the indication versus for the drug
Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+70 | 79 | 18k | 14mo |
|
About the Pricing category
List prices, negotiated prices, and cost per milligram compared honestly across formats. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+1 | 5 | 18k | 15mo |
|
Coverage for the indication versus for the drug — a second dataset
On the subject in the title: Coverage for the indication versus for the drug — a second dataset Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is…
|
+46 | 50 | 41k | 16mo |
|
Second pass at: Manufacturer assistance programmes and their eligibility rules
Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in…
|
+13 | 17 | 1.8k | 16mo |
|
Prior authorisation: what the criteria usually require
On the subject in the title: Prior authorisation: what the criteria usually require Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+9 | 13 | 3.2k | 17mo |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines…
|
+39 | 43 | 510 | 17mo |
|
Cost per milligram, computed honestly across formats
Posting this under the heading it deserves: Cost per milligram, computed honestly across formats Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
|
2 | 47k | 18mo | |
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
Coming back to: Cost per delivered dose, which is the number that matters
On the subject in the title: Cost per delivered dose, which is the number that matters Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
+6 | 10 | 2.5k | 19mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
|
+127 | 150 | 41k | 20mo |
|
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+23 | 28 | 45k | 21mo |
|
Pen wastage and its effect on real cost
Pen wastage and its effect on real cost Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what determines…
|
+29 | 33 | 19k | 21mo |
|
Hoarding and why it makes a shortage worse
Posting this under the heading it deserves: Hoarding and why it makes a shortage worse Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
2 | 12k | 22mo |